Compare Goldman Sachs Group Inc (GS) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Tenet Healthcare Corporation — how do they compare? Goldman Sachs Group Inc trades at $1,098.78 (market cap $339.87B), while Tenet Healthcare Corporation trades at $198.5 (market cap $16.57B). The key difference: Goldman Sachs Group Inc is far larger — about 20.5× Tenet Healthcare Corporation's market cap, and Goldman Sachs Group Inc pays a 1.56% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| GS | THC | |
|---|---|---|
Market Cap | $339.87B | $16.57B |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $244.80 |
52-Week Low | $700.41 | $148.38 |
Dividend Yield | 1.56% | — |
Enterprise Value | — | $26.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,140, up 9.0% over 24 hours, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $20.98 versus $14.47, and revenue growth from $58.28B in 2025 to $60.4B projected for 2026. Recent news highlights Goldman's role in leading high-profile IPOs including Anthropic, signaling strong investment banking pipeline strength.
Outlook remains positive with analyst consensus price target of $1,140K and 40% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include volatile cash flow patterns and high leverage, while institutional sentiment supports continued growth from M&A activity and AI-driven market opportunities.
Tenet Healthcare (THC) trades at $199.10, up 8.39% over the past day, with strong fundamental metrics including a P/E of 10 and net income margin of 7.79%. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $4.82 surpassing the $4.17 estimate. Technical indicators show a bearish trend with support at $187 and resistance at $197, while analyst sentiment remains overwhelmingly positive with 26 buy ratings and a consensus price target of $235.88.
The outlook for THC is favorable due to robust earnings performance and attractive valuation, though near-term price volatility and competitive pressures in healthcare pose risks. Revenue growth is projected to increase from $21.3B in 2025 to $21.9B in 2026, supporting further upside if execution continues. Investors should monitor Q2 2026 earnings due July 24, 2026, for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
